坏死性凋亡与癌症
Necroptosis and Cancer.
作者信息
Najafov Ayaz, Chen Hongbo, Yuan Junying
机构信息
Department of Cell Biology, Harvard Medical School, 240 Longwood Ave. Boston, MA 02115.
Department of Pediatrics, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, China.
出版信息
Trends Cancer. 2017 Apr;3(4):294-301. doi: 10.1016/j.trecan.2017.03.002.
Abstract
Necroptosis is a programmed lytic cell death pathway, deregulation of which is linked to various inflammatory disorders. Escape from programmed cell death and inflammation play a significant role in cancer, and therefore, investigating the role of necroptosis in cancer has been of high interest. Necroptosis has been shown to promote cancer metastasis and T cells death. Escape from necroptosis via loss of RIPK3 expression is a feature of some cancers. While necroptosis is a promising novel target for cancer therapies, further investigation into its biological role in carcinogenesis is warranted. In this article, we review the recently-identified interplay points between necroptosis and cancer, and outline major biological questions that require further inquiry on the road to targeting this pathway in cancer.
摘要
坏死性凋亡是一种程序性溶解性细胞死亡途径，其失调与多种炎症性疾病相关。逃避程序性细胞死亡和炎症在癌症中起着重要作用，因此，研究坏死性凋亡在癌症中的作用一直备受关注。已表明坏死性凋亡可促进癌症转移和T细胞死亡。通过RIPK3表达缺失逃避坏死性凋亡是某些癌症的一个特征。虽然坏死性凋亡是癌症治疗的一个有前景的新靶点，但有必要进一步研究其在致癌过程中的生物学作用。在本文中，我们综述了最近发现的坏死性凋亡与癌症之间的相互作用点，并概述了在将该途径作为癌症治疗靶点的道路上需要进一步探究的主要生物学问题。
相似文献
1
Necroptosis and Cancer.坏死性凋亡与癌症
Trends Cancer. 2017 Apr;3(4):294-301. doi: 10.1016/j.trecan.2017.03.002.
2
The role of necroptosis in cancer: A double-edged sword?细胞坏死性凋亡在癌症中的作用：一把双刃剑？
Biochim Biophys Acta Rev Cancer. 2019 Apr;1871(2):259-266. doi: 10.1016/j.bbcan.2019.01.006. Epub 2019 Feb 1.
3
The role of necroptosis, an alternative form of cell death, in cancer therapy.细胞程序性坏死（细胞坏死的一种形式）在癌症治疗中的作用。
Expert Rev Anticancer Ther. 2013 Jul;13(7):883-93. doi: 10.1586/14737140.2013.811180.
4
Relevance of necroptosis in cancer.坏死性凋亡在癌症中的相关性。
Immunol Cell Biol. 2017 Feb;95(2):137-145. doi: 10.1038/icb.2016.120. Epub 2016 Dec 6.
5
A decade of cell death studies: Breathing new life into necroptosis.细胞死亡研究的十年：为细胞坏死作用带来新的生命。
Pharmacol Ther. 2021 Apr;220:107717. doi: 10.1016/j.pharmthera.2020.107717. Epub 2020 Oct 24.
6
Apoptosis, autophagy, necroptosis, and cancer metastasis.细胞凋亡、自噬、坏死性凋亡与癌症转移
Mol Cancer. 2015 Feb 21;14:48. doi: 10.1186/s12943-015-0321-5.
7
Necroptosis in cancer: An angel or a demon?癌症中的坏死性凋亡：天使还是恶魔？
Tumour Biol. 2017 Jun;39(6):1010428317711539. doi: 10.1177/1010428317711539.
8
Necroptotic cell death in anti-cancer therapy.在癌症治疗中的细胞坏死性细胞死亡。
Immunol Rev. 2017 Nov;280(1):207-219. doi: 10.1111/imr.12583.
9
Molecular Cell Biology of Apoptosis and Necroptosis in Cancer.癌症中细胞凋亡和坏死性凋亡的分子细胞生物学
Adv Exp Med Biol. 2016;930:1-23. doi: 10.1007/978-3-319-39406-0_1.
10
Homoharringtonine, a clinically approved anti-leukemia drug, sensitizes tumor cells for TRAIL-induced necroptosis.高三尖杉酯碱是一种临床批准的抗白血病药物，可使肿瘤细胞对TRAIL诱导的坏死性凋亡敏感。
Cell Commun Signal. 2015 Apr 29;13:25. doi: 10.1186/s12964-015-0103-0.
引用本文的文献
1
Harnessing cuproptosis: a new avenue for targeted cancer therapies.利用铜死亡：靶向癌症治疗的新途径。
Apoptosis. 2025 Sep 12. doi: 10.1007/s10495-025-02174-1.
2
Metabolic cell death in cancer: mechanisms and therapeutic potential.癌症中的代谢性细胞死亡：机制与治疗潜力
Apoptosis. 2025 Sep 9. doi: 10.1007/s10495-025-02176-z.
3
Very long-chain fatty acids accumulate in breast cancer tissue and serum.极长链脂肪酸在乳腺癌组织和血清中蓄积。
Cancer Cell Int. 2025 Aug 4;25(1):296. doi: 10.1186/s12935-025-03928-2.
4
Potential value and cardiovascular risks of programmed cell death in cancer treatment.程序性细胞死亡在癌症治疗中的潜在价值与心血管风险
Front Pharmacol. 2025 Jul 3;16:1615974. doi: 10.3389/fphar.2025.1615974. eCollection 2025.
5
Construction of a prognostic model for lung adenocarcinoma based on necroptosis genes and its exploration of the potential for tumor immunotherapy.基于坏死性凋亡基因构建肺腺癌预后模型及其肿瘤免疫治疗潜力探索
Transl Cancer Res. 2025 May 30;14(5):2563-2579. doi: 10.21037/tcr-24-2165. Epub 2025 May 26.
6
Piperazine-Substituted Pyranopyridines Exhibit Antiproliferative Activity and Act as Inhibitors of HBV Virion Production.哌嗪取代的吡喃并吡啶具有抗增殖活性，并可作为乙肝病毒颗粒产生的抑制剂。
Int J Mol Sci. 2025 Apr 23;26(9):3991. doi: 10.3390/ijms26093991.
7
Epigenetic Inactivation of RIPK3-Dependent Necroptosis Augments Cisplatin Chemoresistance in Human Osteosarcoma.RIPK3 依赖性坏死性凋亡的表观遗传失活增强了人骨肉瘤对顺铂的化疗耐药性。
Int J Mol Sci. 2025 Apr 18;26(8):3863. doi: 10.3390/ijms26083863.
8
Research progress of ferroptosis pathway and its related molecular ubiquitination modification in liver cancer.铁死亡途径及其相关分子泛素化修饰在肝癌中的研究进展
Front Oncol. 2025 Mar 21;15:1502673. doi: 10.3389/fonc.2025.1502673. eCollection 2025.
9
Machine learning-based bulk RNA analysis reveals a prognostic signature of 13 cell death patterns and potential therapeutic target of SMAD3 in acute myeloid leukemia.基于机器学习的批量RNA分析揭示了急性髓系白血病中13种细胞死亡模式的预后特征以及SMAD3的潜在治疗靶点。
BMC Cancer. 2025 Feb 15;25(1):273. doi: 10.1186/s12885-025-13658-3.
10
Advances in non-apoptotic regulated cell death: implications for malignant tumor treatment.非凋亡调控性细胞死亡的进展：对恶性肿瘤治疗的启示
Front Oncol. 2025 Jan 30;15:1519119. doi: 10.3389/fonc.2025.1519119. eCollection 2025.
本文引用的文献
1
Blocking TCR restimulation induced necroptosis in adoptively transferred T cells improves tumor control.阻断过继转移T细胞中TCR再刺激诱导的坏死性凋亡可改善肿瘤控制。
Oncotarget. 2016 Oct 25;7(43):69371-69383. doi: 10.18632/oncotarget.12674.
2
RIPK1 mediates axonal degeneration by promoting inflammation and necroptosis in ALS.受体相互作用蛋白激酶1（RIPK1）通过促进肌萎缩侧索硬化症（ALS）中的炎症和坏死性凋亡介导轴突退变。
Science. 2016 Aug 5;353(6299):603-8. doi: 10.1126/science.aaf6803.
3
Tumour-cell-induced endothelial cell necroptosis via death receptor 6 promotes metastasis.肿瘤细胞诱导内皮细胞通过死亡受体 6发生坏死性凋亡促进转移。
Nature. 2016 Aug 11;536(7615):215-8. doi: 10.1038/nature19076. Epub 2016 Aug 3.
4
RIPK3 Restricts Myeloid Leukemogenesis by Promoting Cell Death and Differentiation of Leukemia Initiating Cells.RIPK3 通过促进白血病起始细胞的死亡和分化来限制髓性白血病发生。
Cancer Cell. 2016 Jul 11;30(1):75-91. doi: 10.1016/j.ccell.2016.06.002.
5
The caspase-8 inhibitor emricasan combines with the SMAC mimetic birinapant to induce necroptosis and treat acute myeloid leukemia.半胱天冬酶-8 抑制剂恩西地平与 SMAC 模拟物 birinapant 联合诱导坏死性凋亡并治疗急性髓系白血病。
Sci Transl Med. 2016 May 18;8(339):339ra69. doi: 10.1126/scitranslmed.aad3099.
6
The necrosome promotes pancreatic oncogenesis via CXCL1 and Mincle-induced immune suppression.坏死小体通过CXCL1和Mincle诱导的免疫抑制促进胰腺癌发生。
Nature. 2016 Apr 14;532(7598):245-9. doi: 10.1038/nature17403. Epub 2016 Apr 6.
7
Necroptosis in Niemann-Pick disease, type C1: a potential therapeutic target.1型尼曼-匹克病中的坏死性凋亡：一个潜在的治疗靶点。
Cell Death Dis. 2016 Mar 17;7(3):e2147. doi: 10.1038/cddis.2016.16.
8
Mixed lineage kinase domain-like protein is a prognostic biomarker for cervical squamous cell cancer.混合谱系激酶结构域样蛋白是宫颈鳞状细胞癌的一种预后生物标志物。
Int J Clin Exp Pathol. 2015 Nov 1;8(11):15035-8. eCollection 2015.
9
Necrostatin-1 reduces intestinal inflammation and colitis-associated tumorigenesis in mice.坏死抑制因子-1可减轻小鼠肠道炎症及与结肠炎相关的肿瘤发生。
Am J Cancer Res. 2015 Oct 15;5(10):3174-85. eCollection 2015.
10
RIPK1 and NF-κB signaling in dying cells determines cross-priming of CD8⁺ T cells.死亡细胞中的RIPK1和NF-κB信号决定CD8⁺ T细胞的交叉启动。
Science. 2015 Oct 16;350(6258):328-34. doi: 10.1126/science.aad0395. Epub 2015 Sep 24.
Zotero 插件